Antifungal therapy for genitourinary infections

Bibliography

• WHITTAKER RH: New concepts of kingdoms of organisms. Science (1969) 163:150–160.
   PubMed Web of Science ®Google Scholar
• RIPPON JW: Medical Mycology. The Pathogenic Fungi and the Pathogenic Actinomycetes. 3rd Edn, WB Saunders. Philadelphia (1988):122–153.
   Google Scholar
• MCGINNIS MR, SIGLER L, RINALDI MG: Some medically important fungi and their common synonyms and names of uncertain application. Clin. Inf. Dis. (1999) 29:728–730.
   PubMedGoogle Scholar
• EDWARDS JE: Invasive candida infections. Evolution of a fungal pathogen. N. Engl. J. Med. (1991) 324:1060–1062.
   PubMed Web of Science ®Google Scholar
• LEDERBERG J, SHOPE RE, OAKS SC Jr.: Emerging infections: microbial threats to health in the United States. National Academy Press, Washington DC (1992).
   Google Scholar
• STERNBERG 5: The emerging fungal threat. Science (1994) 266: 1632-1634.
   Google Scholar
• ••An admonition for the future.
   Google Scholar
• EDMUND MB, WALLACE SE, MCCLISH DK, PFALLER MA, JONES RN, WENZEL RP: Nosocomial bloodstream infections in United States Hospitals: a three-year analysis. Clin. Inf. Dis. (1999) 29:239–244.
   PubMedGoogle Scholar
• RICHARDS MJ, EDWARDS JR, CULVER DH, GAYNES RP: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Grit. Care Med. (1999) 27:887–892.
   Google Scholar
• •Good epidemiological data.
   Google Scholar
• BECK-SAGUE CM, JARVIS WR, THE NATIONAL NOSOCOMIAL INFECTIONS SURVEILLANCE SYSTEM: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990.1 Infect. Dis. (1993) 167:1247–1251.
   PubMed Web of Science ®Google Scholar
• VINCENT J-L, BIHARI DJ, HEMMER M: The prevalence of nosocomial infection in intensive care units in Europe. JAMA (1995) 274:639–644.
   PubMedGoogle Scholar
• REES JR, PINNER RW, HAJJEH RA, BRANDT ME, REIN GOLD AL: The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: Results of population-based laboratory active surveillance. Clin. Inf. Dis. (1998) 27:1138–1147.
   PubMed Web of Science ®Google Scholar
• WALSH TJ: Recent advances in the treatment of systemic fungal infections. Meth. Find. Exp. Clin. Phannacol. (1987) 9:769–778.
   PubMed Web of Science ®Google Scholar
• MEDOFF G, KOBAYASHI GS: Strategies in the treatment of systemic fungal infections. New Eng. J. Med. (1980) 302:145–155.
   PubMed Web of Science ®Google Scholar
• DEAN JL, WOLF JE, RANZINI AC, LAUGHLIN MA: Use of amphotericin B during pregnancy: case report and review. Clin. Inf. Dis. (1994) 18:364–368.
   PubMed Web of Science ®Google Scholar
• GIGLIOTTI F, SHENEP JL, LOTT L, THORNTON D: Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin. Br. I Infect. Dis (1987) 156:784–789.
   PubMed Web of Science ®Google Scholar
• DACAMARA CC, LANE TW: Dantrolene for amphotericin B induced rigors (letter). Arch. Intern. Med. (1987) 147:2220.
   Google Scholar
• STAMM AM, DIASIO RB, DISMUKES WE et al.: Toxicity of amphotericin B plus flucytosine in 104 patients with cryptococcal meningitis. Am. j Med. (1987) 83:236–242.
   PubMed Web of Science ®Google Scholar
• BRANCH RA. Prevention of amphotericin B induced renal impairment. Arch. Intern. Med. (1988) 148:2389–2394.
   PubMedGoogle Scholar
• SMITH SR, GALLOWAY MJ, REILLY JT, DAVIES TJ: Amiloride prevents amphotericin B related hypokalemia in neutropenic patients.' Clin. Path& (1988) 41:494–497.
   PubMed Web of Science ®Google Scholar
• SCHMITT H-J: New methods of delivery of amphotericin B. Clin. Inf. Dis. (1993) 17\(Suppl. 2):5501–5506.
   Google Scholar
• WIEBE VJ, DEGREGORIO MW: Liposome encapsulated amphotericin B: A promising new treatment for disseminated fungal infections. Rev Infect. Dis. (1988) 10:1097–1101.
   PubMedGoogle Scholar
• •A good review of liposomal amphotericin B.
   Google Scholar
• GOKHALE PC, BARAPATRE RJ, ADVANI SH, KSHIRSAGAR NA, PANDYA SK: Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal Amphotericin Br. I Cancer Res. Clin. Omni (1993) 119:569–571.
   PubMed Web of Science ®Google Scholar
• SPATH-SCHWALBE E, KOSCHUTH A, DIETZMAN A, SCHANZ J, POSSINGER K: Successful us of liposomal amphotericin B in a case of amphotericin B-induced nephrogenic diabetes insipidus. Clin. Inf. Dis. (1999) 28:680–681.
   PubMedGoogle Scholar
• RALPH ED, BARBER KR, GRANT CWM: Liposomal amphotericin B: an effective nontoxic preparation for the treatment of urinary tract infections caused by Candida albicans. Am. Nephrol (1991) 11:118–122.
   PubMedGoogle Scholar
• SEIDENFELD SM, COOPER BH, SMITH JW et al.: Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species. Infect. Dis. (1983) 147:116–119.
   Google Scholar
• WINGARD JR, KUBILIS P, LEE L et al.: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Inf. Dis. (1999) 29:1402–1407.
   PubMed Web of Science ®Google Scholar
• CRONIN JE, BARRON RL: Anaphylaxis upon switching lipid-containing amphotericin B formulations. Clin. In]: D (1999) 28: 1342.
   PubMedGoogle Scholar
• WISE GJ, GOLDMAN WM, GOLDBERG PE, ROTHENBERG R: Miconazole: a cost effective antifungal genitourinary irrigant.J. Um] (1987) 138:1413–1415.
   Google Scholar
• WISE GJ, GOLDBERG PE, KOZINN PJ: Do the imidazoles have a role in the management of genitourinary fungal infections?' Urol. (1985) 133:61–64.
   Google Scholar
• TRENK D, BRETT W, JAHNCHEN E, BIRNBAUM D: Time course of cyclosporine/itraconazole interaction. Lancet (1987) 1335–1336.
   PubMedGoogle Scholar
• RICHARDSON K, COOPER K, MARRIOTT MS, TARBIT MH, TROKE PF, WHITTLE PJ: Discovery of fluconazole, a novel antifungal agent. Rev In]: Dis (1990) 12\(Suppl. 3):5267–5271.
   Google Scholar
• COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. NEM (1994) 330:263–272.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of anti-fungal drugtherapy.
   Google Scholar
• LEE BE, FEINBERG M, ABRAHAM JJ, MURTHY ARK: Congenital malformations in an infant born to a woman treated with fluconazole. Ped. In]: Dis. J. (1992) 12:1062–1064.
   Google Scholar
• Urinary Tract Candidosis. Lancet (1988) 2: 1000.
   PubMedGoogle Scholar
• NASSOURA Z, IVATURY RR, SIMON RJ, JABBOUR N, STAHL WM: Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy. Trauma (1993) 35:290–294.
   PubMedGoogle Scholar
• FAN-HARVARD P, O'DONOVAN C, SMITH SM, OH J, BAMBERGER M, ENG RHK: Oral fluconazole versus amphotericin B bladder irrigations for treatment of candidal funguria. Clin. Inf. Dis. (1995) 21:960–965.
   PubMedGoogle Scholar
• SOBEL JD, KAUFFMAN CA,MCKINSEY D et al.: Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. Clin. Inf. Dis. (2000) 30:19–24.
   Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ et al.: In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592 and voriconazole. Antimicrob. Agents Chemother. (1998) 42:3242–3244.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotercin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl. Med. (2002) 346:225–234.
   PubMed Web of Science ®Google Scholar
• CHARNOW JA: First Drug in new class of antifungals approved. Intern. Med. World Rep. (2001) 16:1–29.
   Google Scholar
• KULBERG BJ, ANAISSIE EJ: Cytokines for opportunistic fungal infections. Res. Immunol (1998) 149:478–488.
   PubMedGoogle Scholar
• WHITE TC, MARR KA, BOWDEN RA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microb. Rey (1998) 11:382–402.
   PubMed Web of Science ®Google Scholar
• ••An excellent summation of molecularfactors that cause fungal resistance.
   Google Scholar
• GHANNOUM MA, RICE LB: Antifungal agents: mode of action, mechanisms of resistance and correlation of these mechanisms with bacterial resistance. Clin. Microbiol Rev (1999) 12:501–517.
   PubMed Web of Science ®Google Scholar
• ••An outstanding review of mechanisms ofdrug resistance in fungi.
   Google Scholar